CA2196207A1 - Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression - Google Patents
Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expressionInfo
- Publication number
- CA2196207A1 CA2196207A1 CA002196207A CA2196207A CA2196207A1 CA 2196207 A1 CA2196207 A1 CA 2196207A1 CA 002196207 A CA002196207 A CA 002196207A CA 2196207 A CA2196207 A CA 2196207A CA 2196207 A1 CA2196207 A1 CA 2196207A1
- Authority
- CA
- Canada
- Prior art keywords
- regulation
- mhc class
- heavy chain
- identification
- chain expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 4
- 230000003828 downregulation Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 2
- 102000043129 MHC class I family Human genes 0.000 abstract 2
- 108091054437 MHC class I family Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Abstract
Infection of human fibroblast cells with human cytomegalovirus (HCMV) causes down-regulation of cell surface expression of MHC class I. A recombinant mutant HCMV which fails to down-regulate class I heavy chain expression is described. A method of controlling down-regulation of MHC class I expression in a cytomegalovirus infected cell, a pharmaceutical composition, a vaccine composition, a method of preventing or reducing susceptibility to acute cytomegalovirus in an individual, and a virus based gene therapy vector are also described.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002328638A CA2328638A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/282,696 US5846806A (en) | 1994-07-29 | 1994-07-29 | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US08/282,696 | 1994-07-29 | ||
PCT/US1995/009799 WO1996004384A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002328638A Division CA2328638A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2196207A1 true CA2196207A1 (en) | 1996-02-15 |
CA2196207C CA2196207C (en) | 2002-04-30 |
Family
ID=23082718
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002195668A Expired - Fee Related CA2195668C (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
CA002328638A Abandoned CA2328638A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
CA002196207A Expired - Fee Related CA2196207C (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002195668A Expired - Fee Related CA2195668C (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
CA002328638A Abandoned CA2328638A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Country Status (11)
Country | Link |
---|---|
US (6) | US5846806A (en) |
EP (2) | EP0775209A1 (en) |
JP (2) | JP4036469B2 (en) |
KR (2) | KR970704884A (en) |
AU (2) | AU709552B2 (en) |
CA (3) | CA2195668C (en) |
FI (2) | FI970352A (en) |
MX (1) | MX9700676A (en) |
NO (2) | NO970369L (en) |
NZ (2) | NZ290718A (en) |
WO (2) | WO1996004383A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032605A1 (en) * | 1996-03-08 | 1997-09-12 | Massachusetts Institute Of Technology | Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases |
PT966301E (en) * | 1996-07-31 | 2005-06-30 | Ortho Mcneil Pharm Inc | IDENTIFICATION OF HUMAN CITOMEGALOVIRUS GENES INVOLVED IN THE NEGATIVE ADJUSTMENT OF MHC HEAVY CHAIN EXPRESSION CLASS I |
WO1998031813A1 (en) * | 1997-01-17 | 1998-07-23 | Roche Diagnostics Gmbh | Inhibitors of antigen presentation by mhc class i molecules |
WO1998047914A2 (en) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gene from the human cytomegalovirus (hcmv) |
EP1045920A1 (en) * | 1998-01-14 | 2000-10-25 | Human Gene Therapy Research Institute | Nucleotide expression systems with reduced immunogenicity for use in gene therapy |
US6100008A (en) * | 1998-09-14 | 2000-08-08 | Ppg Industries Ohio, Inc. | Positive photoresist with improved contrast ratio and photospeed |
WO2000046361A1 (en) * | 1999-02-02 | 2000-08-10 | Oregon Health Sciences University | Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells |
WO2002018954A2 (en) | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
US20030118568A1 (en) * | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
KR20050093003A (en) * | 2004-03-17 | 2005-09-23 | 이재본 | Micro turbine generator |
JP2010517544A (en) | 2007-02-07 | 2010-05-27 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Recombinant antigen of human cytomegalovirus (HCMV) |
WO2009073330A2 (en) * | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
CA2793959C (en) * | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
PT2772265T (en) | 2010-05-14 | 2018-04-20 | Univ Oregon Health & Science | Recombinant hcmv and rhcmv vectors and uses thereof |
AU2012267786B2 (en) | 2011-06-10 | 2017-08-03 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
WO2014138209A1 (en) | 2013-03-05 | 2014-09-12 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
BR112017000696B1 (en) | 2014-07-16 | 2023-10-03 | Oregon Health & Science University | ISOLATED POLYNUCLEOTIDE |
CN114317611A (en) * | 2015-02-10 | 2022-04-12 | 俄勒冈健康与科学大学 | Methods and compositions useful for generating atypical CD8+ T cell responses |
US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
JP2019531745A (en) | 2016-10-18 | 2019-11-07 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Cytomegalovirus vector that induces T cells restricted by major histocompatibility complex E molecules |
EP3697806A4 (en) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058598A (en) * | 1974-10-18 | 1977-11-15 | Harold Stern | Cytomegalovirus attenuation method and vaccine |
US4689225A (en) * | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
US4877737A (en) * | 1985-09-06 | 1989-10-31 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
WO1988010311A1 (en) * | 1987-06-26 | 1988-12-29 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
AU3550489A (en) * | 1988-05-09 | 1989-11-29 | Children's Hospital Incorporated, The | Vectors encoding hcmv glycoprotein and expression products |
SG49046A1 (en) * | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
-
1994
- 1994-07-29 US US08/282,696 patent/US5846806A/en not_active Expired - Fee Related
-
1995
- 1995-06-02 US US08/459,586 patent/US5720957A/en not_active Expired - Fee Related
- 1995-06-02 US US08/458,544 patent/US5753476A/en not_active Expired - Fee Related
- 1995-07-28 CA CA002195668A patent/CA2195668C/en not_active Expired - Fee Related
- 1995-07-28 WO PCT/US1995/009607 patent/WO1996004383A1/en not_active Application Discontinuation
- 1995-07-28 JP JP50665896A patent/JP4036469B2/en not_active Expired - Fee Related
- 1995-07-28 EP EP95927533A patent/EP0775209A1/en not_active Withdrawn
- 1995-07-28 NZ NZ290718A patent/NZ290718A/en unknown
- 1995-07-28 AU AU31535/95A patent/AU709552B2/en not_active Ceased
- 1995-07-31 MX MX9700676A patent/MX9700676A/en unknown
- 1995-07-31 WO PCT/US1995/009799 patent/WO1996004384A1/en not_active Application Discontinuation
- 1995-07-31 AU AU32745/95A patent/AU708983B2/en not_active Ceased
- 1995-07-31 EP EP95929364A patent/EP0772681A1/en not_active Withdrawn
- 1995-07-31 NZ NZ291571A patent/NZ291571A/en unknown
- 1995-07-31 CA CA002328638A patent/CA2328638A1/en not_active Abandoned
- 1995-07-31 CA CA002196207A patent/CA2196207C/en not_active Expired - Fee Related
- 1995-07-31 US US08/509,214 patent/US5843458A/en not_active Expired - Fee Related
- 1995-07-31 JP JP8506737A patent/JPH10506268A/en not_active Ceased
-
1997
- 1997-01-28 NO NO970369A patent/NO970369L/en not_active Application Discontinuation
- 1997-01-28 NO NO970370A patent/NO970370L/en not_active Application Discontinuation
- 1997-01-28 FI FI970352A patent/FI970352A/en unknown
- 1997-01-28 FI FI970351A patent/FI970351A0/en unknown
- 1997-01-29 KR KR1019970700612A patent/KR970704884A/en not_active Application Discontinuation
- 1997-01-29 KR KR1019970700611A patent/KR970704883A/en not_active Application Discontinuation
- 1997-10-07 US US08/946,598 patent/US5906935A/en not_active Expired - Fee Related
-
1998
- 1998-03-16 US US09/039,802 patent/US5908780A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH10506268A (en) | 1998-06-23 |
WO1996004383A1 (en) | 1996-02-15 |
NO970370D0 (en) | 1997-01-28 |
NO970369D0 (en) | 1997-01-28 |
AU709552B2 (en) | 1999-09-02 |
AU3153595A (en) | 1996-03-04 |
CA2195668C (en) | 2004-09-21 |
FI970352A0 (en) | 1997-01-28 |
US5846806A (en) | 1998-12-08 |
AU3274595A (en) | 1996-03-04 |
JP4036469B2 (en) | 2008-01-23 |
NO970369L (en) | 1997-03-21 |
EP0772681A1 (en) | 1997-05-14 |
KR970704883A (en) | 1997-09-06 |
CA2196207C (en) | 2002-04-30 |
KR970704884A (en) | 1997-09-06 |
US5753476A (en) | 1998-05-19 |
FI970352A (en) | 1997-01-28 |
NZ290718A (en) | 1999-03-29 |
CA2195668A1 (en) | 1996-02-15 |
US5843458A (en) | 1998-12-01 |
US5906935A (en) | 1999-05-25 |
MX9700710A (en) | 1997-09-30 |
NO970370L (en) | 1997-03-24 |
FI970351A (en) | 1997-01-28 |
US5908780A (en) | 1999-06-01 |
JPH10503378A (en) | 1998-03-31 |
AU708983B2 (en) | 1999-08-19 |
NZ291571A (en) | 1999-01-28 |
CA2328638A1 (en) | 1996-02-15 |
MX9700676A (en) | 1997-04-30 |
US5720957A (en) | 1998-02-24 |
EP0775209A1 (en) | 1997-05-28 |
FI970351A0 (en) | 1997-01-28 |
WO1996004384A1 (en) | 1996-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2196207A1 (en) | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression | |
AU4032893A (en) | Human papilloma virus genes and their use in gene therapy | |
BR9712366A (en) | Herpes simplex hsv2 gd2 gene isolated, plasmid comprising the same, and processes to induce an immune response against hsv2 gd2 in an individual, to treat an individual who is infected with hsv, and to prevent an individual from becoming infected with hsv | |
FR2712603B1 (en) | Recombinant viruses, preparation and use in gene therapy. | |
GB2217718B (en) | Recombinant viruses,vaccines containing them and in vitro cell cultures thereof | |
AU3066992A (en) | Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids | |
PT92931A (en) | Treatment of host cells - for infection or hyper-proliferative disorder characterised by presence of trans-activating factor, using cis-acting factor | |
CA2072627A1 (en) | Recombinant herpes simplex viruses vaccines and methods | |
AU3824595A (en) | Recombinant negative strand RNA virus expression systems and vaccines | |
FR2647808B1 (en) | RECOMBINANT POXVIRUS AND HERPES VIRUS VACCINE CONTAINING THE POXVIRUS | |
AUPN477695A0 (en) | Gene therapy | |
EP0564539A4 (en) | Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy | |
CA2130360A1 (en) | Sulfonic Acid Derivatives in the Treatment of Viral Diseases | |
FR2702152B1 (en) | Recombinant viruses and their use in gene therapy. | |
CA2124769A1 (en) | Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors | |
FR2712602B1 (en) | Recombinant viruses, preparation and use in gene therapy. | |
BR9806866A (en) | Expression cassette and its use, expression cassette strain, nucleic acid vector, viral strain, pharmaceutical composition, and, processes to study the function of one or more heterologous genes in a eukaryotic cell, to produce an hsv strain, for treating the human or animal body and for performing gene therapy on a human or animal, and, vaccine. | |
DE3782867D1 (en) | Human cytomegalovirus phospho-protein | |
AU5008296A (en) | Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy | |
AU7665396A (en) | Recombinant viruses containing mobile genetic elements and methods of use in gene therapy | |
IL88371A0 (en) | Directed integration of genes into a plant genome and recombinant dna,expression vectors and host cells used therefor | |
AU1347292A (en) | Methods of transcriptionally modulating gene expression of viral genes and other genes | |
NZ324157A (en) | Conditionally replicating viral vectors and their use in treating HIV | |
ATE360061T1 (en) | REPLICATION-DEFECTIVE MUTANTS OF HERPES VIRUS | |
AU3410889A (en) | Novel recombinant vaccinia virus expression vectors and method of selecting same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |